Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat for Prevention of CI-AKI in CKD Stage 3
NCT05264584Completed
- Sponsor
- Ain Shams University
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of febuxostat in contrast-induced nephropathy (CIN) (2 arms), sponsored by Ain Shams University. Primary endpoint: Prevention of Contrast Induced Acute Kidney Injury. Started Dec 2020; status: completed.
02
Drugs
febuxostat
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT05264584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264584.